September 21, 2014 7:10 AM ET

Pharmaceuticals

Company Overview of Edge Therapeutics, Inc.

Company Overview

Edge Therapeutics, Inc., a hospital-focused biopharmaceutical company, designs and develops implantable technology for direct delivery of therapeutic compounds to the site of brain injury. Its drugs cover therapeutic areas, such as spontaneous brain hemorrhage, traumatic brain injuries, and brain surgeries. The company develops NimoGel and NimoVent to prevent delayed cerebral ischemia, a catastrophic delayed complication after subarachnoid hemorrhage. Its therapeutics are delivered to patients in the United States and internationally. The company was founded in 2009 and is based in New Providence, New Jersey.

139 South Street

Suite 102

New Providence, NJ 07974

United States

Founded in 2009

Phone:

800-208-3343

Fax:

800-208-3433

Key Executives for Edge Therapeutics, Inc.

Co-Founder
Chief Financial Officer
Age: 54
Chief Accounting and Operations Officer
Compensation as of Fiscal Year 2014.

Edge Therapeutics, Inc. Key Developments

Edge Therapeutics, Inc. Obtains $10 Million Venture Loan Facility with Hercules Technology Growth Capital, Inc

Edge Therapeutics, Inc. announced that it has obtained up to $10 million in venture debt financing from Hercules Technology Growth Capital, Inc. to support the continued development of EG-1962, the company's lead product candidate. Edge is developing EG-1962 to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage. The company believes that EG-1962 can become the new standard of care for patients suffering from a ruptured brain aneurysm who receive an intraventricular catheter. The $10 million in funding from Hercules is in the form of secured indebtedness. Payments under the loan agreement are interest only for 12 months, followed by 30 equal monthly payments of principal and interest through the scheduled maturity date on March 1, 2018.

Edge Therapeutics Initiates Enrollment of Second Cohort in Phase 1/2 NEWTON Study of EG-1962 for Improvement of Outcome after Ruptured Brain Aneurysm

Edge Therapeutics announced that it has initiated patient enrollment in the second cohort of the NEWTON study, a multicenter, randomized, controlled, open-label, Phase 1/2 clinical trial of the company's lead product candidate, EG-1962. The NEWTON (Nimodipine microparticles to Enhance recovery While reducing TOxicity after subarachNoid hemorrhage) study is evaluating the safety, tolerability and pharmacokinetics of EG-1962 compared to the current standard of care, oral nimodipine, in patients with aneurysmal subarachnoid hemorrhage (aSAH). The company is also assessing patient functional outcomes at 30 and 90 days, which it believes will be indicative of the potential efficacy of EG-1962. EG-1962 is a novel polymeric nimodipine microparticle utilizing Edge's proprietary Precisa(TM) development platform and is being developed to improve patient outcome after aSAH, also commonly referred to as ruptured brain aneurysm.

Edge Therapeutics, Inc. Announces Opening of New Corporate Headquarters

Edge Therapeutics, Inc. announced that the company has opened its new corporate headquarters at 200 Connell Drive, Suite 1600, Berkeley Heights, New Jersey.

Similar Private Companies By Industry

Company Name Region
Physician Choice, Inc. United States
Horizon Pharma USA, Inc. United States
PediatRx, Inc. United States
Bioponic Phytoceuticals, Inc. United States
ReVision Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 8, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Edge Therapeutics, Inc., please visit www.edgetherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.